Publications by authors named "Yuta Taniuchi"

Claim this Profile
S
Single- and Multiple-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1128, a Novel Peroxisome Proliferator-activated Receptor δ Modulator, in Healthy Participants.
Yuta Taniuchi, J W Olivier van Till, Tomasz Wojtkowski, Junko Toyoshima, Akira Koibuchi

Clin Pharmacol Drug Dev· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, open-label, single-dose micro tracer mass balance study of C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry.
Daisuke Miyatake, Naoyuki Nakada, Akitsugu Takada, Kota Kato, Yuta Taniuchi

Drug Metab Pharmacokinet· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD.
Tobias E Larsson, Chisato Kameoka, Ikumi Nakajo, Yuta Taniuchi, Satoshi Yoshida

Kidney Int Rep· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Pharmacological and clinical profile of nitisinone (Orfadin(®) Capsules): a therapeutic agent for hereditary tyrosinemia type 1].
Hideaki Minoura, Megumi Iwai, Yuta Taniuchi, Masataka Katashima, Hideyuki Takahashi

Nihon Yakurigaku Zasshi· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Takeshi Kadokura, Wenhui Zhang, Walter Krauwinkel, Stefanie Leeflang, James Keirns, Yuta Taniuchi

Clin Pharmacokinet· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of food on the pharmacokinetics of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects.
Takeshi Kadokura, Yuta Taniuchi, Hiroshi Inoue, Masako Saito, Mioko Iwahana

Int J Clin Pharmacol Ther· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.
Tsukasa Ishihara, Norio Seki, Fukushi Hirayama, Masaya Orita, Hiroyuki Koshio, Yuta Taniuchi

Bioorg Med Chem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.
Hiroyuki Koshio, Fukushi Hirayama, Tsukasa Ishihara, Ryouta Shiraki, Takeshi Shigenaga, Yuta Taniuchi

Bioorg Med Chem· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.
Hiroyuki Koshio, Fukushi Hirayama, Tsukasa Ishihara, Hiroyuki Kaizawa, Takeshi Shigenaga, Yuta Taniuchi

Bioorg Med Chem· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity.
Hiroyuki Koshio, Fukushi Hirayama, Tsukasa Ishihara, Yuta Taniuchi, Kazuo Sato

Bioorg Med Chem· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.
Fukushi Hirayama, Hiroyuki Koshio, Naoko Katayama, Tsukasa Ishihara, Hiroyuki Kaizawa, Yuta Taniuchi

Bioorg Med Chem· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Susumu Watanuki, Shunichiro Hachiya, Yuta Taniuchi

Bioorg Med Chem· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
Fukushi Hirayama, Hiroyuki Koshio, Naoko Katayama, Hiroyuki Kurihara, Yuta Taniuchi

Bioorg Med Chem· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis